| Dear Voornaam,
Welcome to your weekly Cancer Research UK Research Update email.
This week we’re marking the end of Professor Karen Vousden’s term as CRUK’s chief scientist.
Karen has been an important face of Cancer Research UK for the research community. She was always available to listen to Cancer Research UK-funded researchers, to understand the challenges they face, and crucially, to ensure their perspectives were represented in debates inside Cancer Research UK.
Working alongside our chief clinician, Charles Swanton, Karen championed the development of our training activities – including the introduction of our Clinical Academic Training Programme – to offer more training options and better support for early career clinical academic researchers.
She oversaw the evolution of our radiobiology and radiation oncology research portfolio, establishing the RadNet network which is leading research in radiobiology towards making radiotherapy even more effective while minimising side effects.
Karen was an active member of both the Discovery Science committee and the Cancer Grand Challenges panel, where she oversaw changes to how we review grants, helped define the challenges, select teams and reviewed the portfolios. Most recently Karen, again with Charlie, led the refresh of our research strategy, which will shape our scientific direction for years to come.
Karen is a Principal Group Leader at the Francis Crick Institute, where her work focuses on tumour suppressors and cancer metabolism. As we say thank you to Karen, we asked her to reflect on where cancer research has come over the last 20 years, and where it might go next. Listen to our latest podcast to hear Karen speak about our changing understanding of p53, her work on HPV and how the life of a researcher has changed over the last 20 years.
Speaking personally, I am enormously grateful for Karen’s input during her time as chief scientist. She has been a consistent voice speaking up for scientific excellence and a remarkable advocate for cancer researchers. We will miss her hugely in this role but look forward to working more closely with her as an active cancer scientist.
Kind regards
Iain
Iain Foulkes
Executive Director Research & Innovation
CEO Cancer Research Horizons
Cancer Research UK |
|
|---|
|
|---|
|
|
September Funding & Research Opportunities |
|
|---|
|
|---|
|
|
October Funding & Research Opportunities |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
|
|
 LIMITED PLACES LEFT ON VENTURE BUILDER INCUBATOR Are you a UK-based PhD student or early-career cancer researcher looking to take your first steps into entrepreneurship? Our Venture Builder Incubator is for you. Join our programme, led in partnership with the University of Edinburgh, to gain the skills and knowledge to translate your cancer research into a fully-fledged, data-driven business.
Apply by 9 September for a chance to secure a £2k grant, as well as one-to-one support, links to investors and access to the University of Edinburgh’s data expertise and wider entrepreneurial ecosystem, mentors and industry champions. |
|
|---|
|  NEW COACHES AVAILABLE FOR OUR LEADERSHIP COACHING PROGRAMME By popular demand, we’ve opened up new spots for our free leadership coaching programme in partnership with Meyler Campbell.
Join our scheme now to boost the professional and personal skills you need to progress in your research career. |
|
|---|
|
|---|
|
|
 A COMING TOGETHER OF MINDS FOR EARLY DETECTION “Part of the challenge of detection is knowing where, or in this case, in whom, to look for cancers.” This is only one of the exciting problems of early detection research we discussed with CRUK Research Programme Manager, Dr Alexis Webb, in our latest research feature.
Read our blog post to find out Alexis’ take on how the momentum is changing for early detection research, the importance of collaboration and why the Early Detection of Cancer Conference is a great opportunity to meet with researchers across different disciplines.
|
|
|---|
|  GET FEEDBACK ON YOUR RESEARCH IDEAS Are you looking for feedback on your research proposal? At NCRI's virtual Proposal Guidance meetings, taking place in November 2022, a bespoke panel of experts is on hand to review your study proposal and provide detailed written feedback to help you develop your work.
Applications are open until 14 September.
|
|
|---|
|
|---|
|
|
CANCER RESEARCH HORIZONS STARTUP’S BREAST CANCER TREATMENT CANDIDATE PROGRESSES TO PHASE 2 CLINICAL TRIALS Join us in congratulating Cancer Research Horizons’ close partner and startup, Artios, on the exciting progress of ART4215, its first-in-class selective, oral, small molecule inhibitor of the Polθ polymerase domain. ART4215 has advanced to phase 2 clinical trial, where it will be evaluated in combination with talazoparib (TALZENNA®), an oral poly (ADP-ribose) polymerase inhibitor, in the treatment of BRCA-negative breast cancer. |
|
|---|
|
|---|
|
|
| | | London, UK 05 September 2022 |
|
|---|
|
|---|
| | | Cambridge, UK 20 September 2022 |
|
|---|
|
|---|
| | | London, UK 10 October 2022 |
|
|---|
|
|---|
| | | Amsterdam, Netherlands 14 October 2022 |
|
|---|
|
|---|
| | | Portland, Oregon, USA 18 October 2022 |
|
|---|
|
|---|
| | | Manchester, UK 15 November 2022 |
|
|---|
|
|---|
| | | East Sussex, UK 04 December 2022 |
|
|---|
|
|---|
|
|
WHAT DID YOU THINK OF THIS EMAIL? We're always looking for ways to improve. Please give us your feedback by clicking below and leaving a comment. |
|
|---|
|
|---|
|
|
| Been forwarded this email?
Subscribe to our newsletter to stay up-to-date. |
|---|
| |
|---|
|
|
|
